Rocket PharmaceuticalsRCKT
RCKT
About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees: 299
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
152% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 23
113% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 45
19% more funds holding
Funds holding: 189 [Q3] → 224 (+35) [Q4]
1.41% more ownership
Funds ownership: 101.68% [Q3] → 103.1% (+1.41%) [Q4]
9% less call options, than puts
Call options by funds: $2.09M | Put options by funds: $2.28M
19% less capital invested
Capital invested by funds: $1.71B [Q3] → $1.38B (-$328M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
115%
upside
Avg. target
$40
559%
upside
High target
$51
743%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Scotiabank Greg Harrison 32% 1-year accuracy 13 / 41 met price target | 743%upside $51 | Sector Outperform Maintained | 12 May 2025 |
Canaccord Genuity Whitney Ijem 30% 1-year accuracy 13 / 43 met price target | 462%upside $34 | Buy Maintained | 12 May 2025 |
Chardan Capital Geulah Livshits 16% 1-year accuracy 11 / 69 met price target | 644%upside $45 | Buy Maintained | 9 May 2025 |
JP Morgan Eric Joseph 41% 1-year accuracy 12 / 29 met price target | 627%upside $44 | Overweight Maintained | 9 May 2025 |
Goldman Sachs Richard Law 45% 1-year accuracy 5 / 11 met price target | 115%upside $13 | Neutral Maintained | 9 May 2025 |
Financial journalist opinion
Based on 3 articles about RCKT published over the past 30 days
Neutral
Business Wire
5 days ago
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Thera.
Neutral
Zacks Investment Research
5 days ago
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
Neutral
Business Wire
6 days ago
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ending March 31, 2025. "Rocket maintained strong momentum during the first quarter, and we look forward to sharing updates of our recent progress starting with initial data from the Phase 1 study.
Positive
Seeking Alpha
1 month ago
Rocket Pharma Out Of Orbit, But Ready For Relaunch
Rocket Pharmaceuticals' gene therapies offer long-term effects for cardiovascular and hematology diseases, addressing severe unmet needs like Danon Disease, which currently requires heart transplants. The near-term outlook driven by clinical milestones for RP-A601, RP-A501, and potential Kresladi approval, with the current share price at $5 offering significant value. Rocket has $372M in cash, funding operations through 1H 2026, but will likely need financing post-positive data readout or Kresladi approval for commercialization.
Neutral
Business Wire
1 month ago
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that management will participate in the 24th Annual Needham Virtual Healthcare Conference taking place on April 8, 2025. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat at 8:45 a.m. ET on Tuesday, April 8. A webcast of the fire.
Neutral
Zacks Investment Research
2 months ago
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Neutral
Business Wire
2 months ago
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2024. “In 2024, we made strong progress in advancing our gene therapy pipeline, underscored by the New England Journal of Medicine publication of the Phase 1 study of.
Positive
Seeking Alpha
3 months ago
Rocket Pharma Is A Buy At These Prices With Promising Data
Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease show strong clinical data, indicating significant market potential. Financially, Rocket Pharma has a limited cash runway of 2–4 quarters, dependent on FDA approvals and successful public offerings.
Negative
Zacks Investment Research
3 months ago
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Benzinga
4 months ago
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Charts implemented using Lightweight Charts™